Status:
UNKNOWN
68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Breast Tumor
Eligibility:
FEMALE
18-80 years
Phase:
EARLY_PHASE1
Brief Summary
This is an open-label positron emission tomography/computed tomography(PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-RM26 in breast tumor patients. 1.85 ...
Detailed Description
The gastrin-releasing peptide receptor (GRPR), also known as bombesin receptor subtype II (BB2), is a member of the G protein-coupled receptor family of bombesin receptors. GRPR is over-expressed in v...
Eligibility Criteria
Inclusion
- patients in suspicion of breast cancer by mammography or ultrasonography,and being able to provide basic information and sign the written informed consent form
Exclusion
- The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study, and undergoing any preceding local or systemic therapies that might interfere with GRPR binding
Key Trial Info
Start Date :
October 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03347864
Start Date
October 1 2016
End Date
October 1 2018
Last Update
November 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730